Cell Therapy Media Market

Cell Therapy Media, Cell Therapy Kits, Cell Therapy Reagents and Cell Therapy Surface Market (2nd Edition): Distribution by Type of Product, Type of Cell Therapy, Scale of Operation, End-User and Key Geographical Regions: Industry Trends and Global Forecasts, 2023-2035

  • Lowest Price Guaranteed From USD 4,799

  • Published
    March 2023

  • Pages
    360

  • View Count
    11089

Example Insights

The image provides context of cell therapy media, kits, reagents and surfaces. Driven by the growing demand for cell therapies, the necessity to comply with the evolving regulatory landscape and to facilitate the manufacturing process, cell therapy developers are increasingly relying on consumable providers This image gives information on types of cell therapy consumables. Leveraging their expertise, over 450 types of kits, media, reagents and extracellular matrices have been manufactured by consumable providers for research and therapeutic purposes This image provides list of cell therapy consumables. The market features the presence of more than 80 firms across the globe; majority of these stakeholders are emerging players based in North America This infographic describes the market landscape of cell therapy kits. A larger proportion of the kits available in the cell therapy domain comprise of different types of reagents; of these, 60% are intended for use with stem cell therapies and nearly 80% are stored in refrigerated conditions This infographic describes the market landscape of cell therapy media. Media developers are offering products for a broad range of cell therapies; nearly 90% of such players are providing media in the volume range of 100 to 500 ml
This infographic describes the market landscape of cell therapy reagents. MPredominantly, the cell therapy reagents are intended to be used at discovery scale of operation for a wide spectrum of functions, including cell expansion and proliferation This image describes the market landscape of cell therapy extracellular matrices. The market landscape of matrices, which typically have a shelf life of 1 to 1.5 years, is well distributed in terms of type of ECM coating and type of formulation The image looks at the competitive landscape across cell therapy extracellular matrices providers. In pursuit of gaining a competitive edge, cell therapy consumable providers are upgrading their existing technologies and expanding their product portfolios This infographic describes the recent developments and initiatives related to cell therapy media, kits, reagents and surfaces. Many companies have undertaken strategic initiatives, including partnerships, acquisitions and expansions, to augment their existing capabilities This image provides the list of potential strategic partners for players involved in this domain. We expect industry stakeholders to continue to forge strategic alliances with niche / specialized players engaged in this domain to further augment their respective product offerings
This image provides the positioning of brands for key players. Over the years, stakeholders within this industry have established strong brand positions by undertaking a range of initiatives to further advance the development of raw materials for cell therapies This infographic describes the pricing strategy matrix that is anticipated to assist players in evaluating the competitive market prices for their products The infographic looks at the demand of various cell therapy consumables. In 2035, the commercial scale of operation is likely to account for 75% of the total demand for cell therapy consumables; this is attributed to the expected surge in the anticipated approvals of multiple cell therapies This image provides details on cell therapy consumables market size. A paradigm shift from animal-based to animal component free formulations, combined with stringent regulatory guidelines, is likely to drive the growth of the cell therapy consumables market at an annualized rate of 12% The image provides segmentaion of cell therapy consumables market. The projected future opportunity for cell therapy consumable providers is expected to be well distributed across different types of end-users and key geographical regions

Report Description

Cell Therapy Media Market Overview

The global cell therapy media, cell therapy kits, cell therapy reagents and other consumables market is estimated to be worth $1.2 billion in 2023 and is expected to grow at compounded annual growth rate (CAGR) of 12% during the forecast period. The therapeutic approach involving the injection of healthy cells in the human body to replace the diseased / non-functioning cells, in order to regulate certain functions, is referred to as cell therapy. In the past few years, this therapeutic approach has emerged as one of the key areas of interest in the healthcare sector, given its ability to treat diseases which were previously considered untreatable. Consequently, driven by the benefits offered by cellular therapies and recent approvals granted by regulatory authorities, the demand for cellular therapies has increased considerably; this has led to a rise in the requirement of cell therapy raw materials. Specifically, cell therapy consumables refer to materials that are used in cell therapy manufacturing. It is worth mentioning that the selection of cell therapy consumables, specifically the cell culture media and supplements, is a crucial step in cell therapy manufacturing as they directly impact the potency and safety of the final product. In this report, we have considered the four predominant types of consumables applicable to cell therapy, namely cell culture media, media kits providing culture media along with the necessary media supplements, reagents and extracellular matrices.

Key Market Insights

The Cell Therapy Media, Cell Therapy Kits, Cell Therapy Reagents and Cell Therapy Surface Market (2nd Edition): Distribution by Type of Product (Culture Media, Kits, Reagents and Extracellular Matrices), Type of Cell Therapy (T-Cell Therapy, Stem Cell Therapy, Dendritic Cell Therapy and NK Cell Therapy), Scale of Operation (Clinical and Commercial), Type of End-User (Industry and Non-Industry) and Key Geographical Regions (North America, Europe, Asia-Pacific, Middle East and North Africa (MENA) and Latin America): Industry Trends and Global Forecasts, 2023-2035 report features an extensive study of the current market landscape and the likely future potential of the cell culture media (supplied alone or in kits as a combination with cell growth supplements), cell culture reagents and ECM  market, over the next 12 years. It highlights the efforts of several stakeholders engaged in this rapidly emerging segment of the pharmaceutical industry. Key inclusions of the report are briefly discussed below.

Growing Demand for Cell Therapies

Since the development of the first cell therapy, this therapeutic segment has garnered significant attention from researchers and medical practitioners. This can be attributed to the fact that cell therapies have been demonstrated to possess a vast potential in the treatment of rare disorders, which were previously considered incurable. The popularity of this therapeutic class of products can also be validated from the fact that, since 2019, more than 1,000 clinical trials focused on cell therapies have been initiated. It is also worth mentioning that over 35 cell and gene therapies have already been commercialized, across various geographical locations, till date. Notable examples of recently approved cell therapies include (in reverse chronological order) Breyanzi® (June 2022), Carvykti™ (February 2022) and Abecma® (March 2021).

Need for High-Quality Cell Therapy Consumables

Driven by the rise in popularity of cell therapies, there is a growth in demand for cell culture media, reagents and surfaces. It is worth mentioning that, amidst the increasing demand for such products, there is a rise in stringency from regulatory authorities to ensure that the quality of raw materials is good. Therefore, to meet the industry needs, cell therapy manufacturers are actively adopting serum free and xeno free products, which are known to reduce the risk of batch-to-batch variability.

Role of Consumables in Commercialization of Cell Therapies

Currently, the marketed cell-based therapies are exorbitantly priced. Even though, with the introduction of automation technologies in cell therapy bioprocessing, the cost and time required for development of such products has reduced significantly, there is still a considerable scope of improvement to make these therapies affordable. 

In this context, it is worth mentioning that consumables, including media, reagents and matrices, currently constitute nearly 25% of the overall cost of cell therapy manufacturing. Optimization of raw materials, by streamlining the production processes, can help mitigate wastage and further reduce the manufacturing cost. Moreover, for commercial applications, it is crucial to obtain consistent outcomes during the manufacturing process. Cell culture media, with chemically defined formulation, provides enhanced consistency for production purposes. 

Current Market Landscape of Cell Therapy Media, Kits, Reagents and Surfaces

The cell therapy consumable providers market landscape features more than 80 companies, which claim to possess the necessary expertise for manufacturing of over 450 research and / or therapeutic grade raw materials. Some of these players also claim to have developed GMP certified facilities for the production of consumables, which are intended to be used for a range of human cells, including T-cells, stem cells, dendritic cells and NK cells. Subsequently, cell therapy media market represents majority share (57%) of consumables offered, followed by the share captured by media and supplement kits (26%), extracellular matrices (14%) and cell culture reagents (3%). The ancillary materials offered by these companies are available in various volumes and can be utilized for numerous functions, such as cell proliferation, cell differentiation and cell isolation. Recent developments in this domain indicate that cell therapy consumable providers are actively expanding their capacity and product portfolio in order to accommodate the current and anticipated demand for cell therapies.

Recent Trends Related to Cell Culture Media

In recent years, there has been a considerable rise in regulatory stringency as well as awareness related to disadvantages of using animal-based medica formulations, in the cell therapy domain. Specifically, animal-based media pose an undesirable risk of transfecting infectious agents. This has resulted in a shift towards the higher adoption of chemically defined, animal-component free (serum-free and xeno-free) media, in the cell culture media market. It is worth mentioning that, currently, majority of the cell culture media are being used for the development of stem cell therapies, followed by those intended for T-cell therapies.

Key Drivers in the Cell Therapy Consumables Market

One of the key drivers of the investments in this market is the success of previously commercialized cell therapies. More than USD 35 billion has already invested in cell therapy domain by private investors. In the last few years, cell therapies have offered a relatively more reliable approach for the treatment of rare diseases. According to a study published in 2019, the prevalence rate of rare diseases is about 263 to 446 million individuals, at any point of time. This necessitates the need for more such life-saving therapies. It is worth highlighting that, by 2030, close to 60 cell and gene therapies are anticipated to receive regulatory approval, further expanding the opportunities associated within the market. These factors will, in turn, lead to a surge in the requirement for cell therapy consumables products, driving significant growth of the domain.

Market Size of the Cell Therapy Consumables Market

Driven by the indubitably rising need for cell therapies, the market for cell therapy media and other consumables is anticipated to grow at a CAGR of 12%, during the period 2023-2035. Specifically, in terms of scale of operation, the demand for consumable products for commercial operations are expected to expand rapidly with the anticipated approval of numerous cell therapies. Additionally, it is worth highlighting that more than 80% of the current market share is captured by players based in North America and Asia-Pacific. 

Example Players in the Cell Therapy Consumables Market

Examples of players engaged in this domain (which have also been captured in this report) include BD Biosciences, Bio-Techne, CellGenix, Corning, Irvine Scientific (Acquired by FUJIFILM), Lonza, Miltenyi Biotech, Sartorius, STEMCELL Technologies and Thermo Fisher Scientific.

Recent Developments in Cell Therapy Media Market

Several recent developments have taken place in the field of cell therapy media. We have outlined some of these recent initiatives below. These developments, even if they took place post the release of our market report, substantiate the overall market trends that have been outlined in our analysis.

  • In May 2023, Lonza launched TheraPEAK® T-VIVO® cell culture medium in order to accelerate cell therapy development. 
  • In March 2023, Sartorious announced the acquisition of Polyplus for the total amount of EUR 2.4 billion with an aim to add innovative solutions of Polyplus to it product portfolio.

Scope of the Report

The study presents an in-depth analysis of the various firms / organizations that are engaged in this domain, across different segments as defined in the below table:

Key Report Attributes Details

Forecast Period

  • 2023 – 2035

Type of Product

  • Extracellular Matrices
  • Kits
  • Media
  • Reagents

Type of Cell Therapy

  • Dendritic cell therapy
  • NK cell therapy
  • Stem cell therapy
  • T-Cell therapy

Scale of Operation

  • Clinical
  • Commercial

Type of End-User

  • Industry
  • Non-Industry

Key Geographical Regions

  • North America
  • Europe
  • Asia-Pacific
  • Middle East and North Africa (MENA)
  • Latin America

Key Companies Profiled

  • BD Biosciences
  • Bio-Techne
  • CellGenix
  • Corning
  • Irvine Scientific (Acquired by FUJIFILM)
  • Lonza
  • Miltenyi Biotech
  • Sartorius
  • STEMCELL Technologies
  • Thermo Fisher Scientific

Customization Scope

  • 15% Free Customization Option

PowerPoint Presentation (Complimentary)

  • Available

Excel Data Packs (Complimentary)

  • Market Landscape Analysis
  • Company Competitiveness Analysis
  • Brand Positioning Analysis
  • Recent Developments and Initiatives
  • Likely Partners Analysis
  • Roots Analysis Competitive Pricing Framework
  • Demand Analysis
  • Market Forecast and Opportunity Analysis

The report presents an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain, across different regions. Amongst other elements, the report includes:

  • An executive summary of the insights captured during our research, offering a high-level view on the current state of the cell therapy consumables market and its likely evolution in the mid-long term.
  • A general introduction to cell therapies, including details related to the development and manufacturing of such therapeutics products, with addition focus on role of raw materials in cell therapy production. It further provides a brief overview of the different types of cell therapy consumables and key challenges associated with their development. 
  • A detailed assessment of the overall market landscape of companies offering cell therapy consumables, based on several relevant parameters, such as year of establishment, company size (in terms of number of employees), location of headquarters, type of product (kits, media, reagents and extracellular matrices), number and location of consumable facilities, accreditations received, type of end-user (industry and non-industry), media compatibility (serum free , xeno free and both), type of cell therapy (T-cell therapies, stem cell therapies, NK cell therapies, dendritic cell therapies and others), type of function (cell proliferation, cell expansion, cell differentiation, cell activation, cell isolation, cell attachment), kit components (supplements / reagents, growth / induction medium, expansion medium, differentiation medium and others), type of ECM coating (laminin, fibronectin, vitronectin, basement membrane extract and others), type of formulation (powder, liquid, pre-coated cultureware), shelf life (6-12 months, 13-18 months, 19-24 months and 25-36 months), scale of operation (discovery, preclinical, clinical and commercial), application area (research use and therapeutic use), storage temperature (refrigerated, frozen, ultra-low and room temperature), as well as volume of media, reagents and extracellular matrices. 
  • A detailed competitiveness analysis of cell therapy consumable providers (kits, media, reagents and extracellular matrices) based on supplier strength (in terms of years of experience and company size), portfolio strength (considering media compatibility, number of unique type of cell therapy, application area, product manufacturing practices and number of consumable facilities) and number of products offered. 
  • A detailed brand positioning analysis of prominent industry players (shortlisted on the basis of strength of service portfolio), highlighting the current perceptions regarding their proprietary brands across different consumable classes.
  • Elaborate profiles of key players offering cell therapy consumables (shortlisted on the basis of portfolio strength and number of products offered); each profile includes a brief overview of the company, along with information on its cell therapy consumables focused product portfolio, consumable facilities, recent developments and an informed future outlook. 
  • An analysis of recent developments within the cell therapy consumable industry, highlighting information on several partnerships and collaborations, mergers and acquisitions, and expansion initiatives that have taken place within this domain, during the period 2016-2022.
  • A list of over 250 cell therapy developers that are anticipated to partner with cell therapy consumable providers; these players have been shortlisted based on several relevant parameters, such as developer strength (which takes into account a company’s size and its experience in this field), pipeline strength and maturity (based on the number of pipeline drugs and affiliated stage of development), and availability of other cell therapy capabilities.
  • A proprietary Roots Analysis competitive pricing framework, which analyzes the competitive position of various companies engaged in this domain, by taking into consideration the prices and features of their consumable offerings (such as media and extracellular matrices). In addition, it presents an equation devised to calculate the likely price of cell therapy consumables based upon their characteristics.
  • An informed estimate of the annual demand for cell therapy consumables (in terms of volume of media required for total number of cells), based on scale of operation and key geographical regions.
  • An in-depth discussion on the upcoming trends and future growth opportunities within the cell therapy consumables market, featuring details related to the significance of automation in cell therapy manufacturing processes and benefits of single use technologies for production of cell therapies.

One of the key objectives of the report was to estimate the current opportunity and the future growth potential of the cell therapy consumables market over the coming years. We have provided an informed estimate on the likely evolution of the market for the period, 2023-2035. Our year-wise projections of the current and forecasted opportunity have been further segmented based on relevant parameters, such as type of product (kits, media, reagents and extracellular matrices), type of cell therapy (t-cell therapies, stem cell therapies, dendritic cell therapies and NK cell therapies), scale of operation (clinical and commercial), type of end-user (industry and non-industry) and key geographical regions (North America, Europe, Asia-Pacific, MENA and Latin America). In order to account for future uncertainties associated with some of the key parameters and to add robustness to our model, we have provided three market forecast scenarios, portraying the conservative, base and optimistic scenarios of the industry’s evolution.

The opinions and insights presented in this study were influenced by discussions conducted with multiple stakeholders in this domain. The report features detailed transcripts of interviews held with the following individuals:

  • Anant Kamath (Chief Operating Officer, Cellular Engineering Technologies)
  • Vishal G. Warke (Director, R&D, Cell Culture and Immunology, HiMedia Laboratories) and Gauri W. Page (Assistant R&D Manager, Animal Cell Culture, HiMedia Laboratories)
  • Michael Maloney (Vice President, Business Development, Cell Culture, Akadeum Life Sciences)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Frequently Asked Questions

Question 1: What are the factors driving the cell therapy consumables market?

Answer: The growing demand for cell therapies, as a result of the increasing number of commercialized cell therapies and the rise in cell therapy focused clinical trials, is one of the key factors driving the growth of the cell therapy consumables market.

Question 2: How many players are engaged in offering cell culture media for manufacturing of cell therapies?

Answer: Currently, more than 65 companies claim to offer different types of cell culture media for the growth, proliferation, expansion and differentiation of numerous types of cell therapies.

Question 3: How many players are engaged in offering kits for manufacturing cell therapies?

Answer: At present, nearly 40 players claim to offer several types of kits required to manufacture cell therapies. These kits comprise of various key components, including supplements / reagents for isolation, activation and differentiation of cells, growth media, differentiation media and expansion media.

Question 4: How many media products are available in the market for culturing cell therapies?

Answer: The current market features the presence of nearly 260 media products, which can be used for the manufacturing of cell therapies intended for culturing of human cells.

Question 5: What are the partnership and collaboration trends in the cell therapy consumables domain?

Answer: At present, distribution agreements, mergers and acquisitions, and product commercialization agreements are the most common types of partnerships inked by stakeholders engaged in the cell therapy consumables domain. 

Question 6: Which geographical segment has the largest market share in the current cell therapy consumables market?

Answer: North America captures the largest share in the current cell therapy consumables market, followed by Asia-Pacific. It is worth mentioning that, within Asia-Pacific, majority of the market share is contributed by China.

Question 7: Which type of product contributes to the largest share of the cell therapy consumables market?

Answer: In 2023, the cell therapy consumables market is expected to be dominated by media. This trend can be attributed to the large quantity of media required for manufacturing of cell therapies.

Contents

Table Of Contents

1. PREFACE
1.1. Introduction
1.2. Key Market Insights
1.3. Scope of the Report
1.4. Research Methodology
1.5. Frequently Asked Questions
1.6. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Context and Background
3.2. Introduction to Cell Therapies
3.3. Comparison of Cell Therapies with Other Biopharmaceuticals
3.4. Classification of Cell Therapy Products
3.5. Overview of Cell Therapy Development and Manufacturing
3.6. Role of Raw Materials in Cell Therapy Development and Manufacturing
3.7. Types of Cell Therapy Consumables
3.8. Key Challenges Associated with Manufacturing of Cell Therapy Consumables
3.9. Future Perspectives

4. MARKET LANDSCAPE
4.1. Chapter Overview
4.2. List of Cell Therapy Kit Providers
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Location of Headquarters
4.2.4. Analysis by Location of Kit Manufacturing Facilities
4.2.5. Analysis by Certifications / Accreditations Received
4.2.6. Analysis by Type of End-User
4.2.7. Analysis by Type of Cell Therapy
4.2.8. Analysis by Type of Function
4.2.9. Analysis by Kit Components
4.2.10. Analysis by Storage Temperature
4.2.11. Analysis by Scale of Operation
4.2.12. Analysis by Application Area
4.2.13. Analysis by Application Area and Geography

4.3. List of Cell Therapy Media Providers
4.3.1. Analysis by Year of Establishment
4.3.2. Analysis by Company Size
4.3.3. Analysis by Location of Headquarters
4.3.4. Analysis by Location of Media Manufacturing Facilities
4.3.5. Analysis by Certifications / Accreditations Received
4.3.6. Analysis by Type of End-User
4.3.7. Analysis by Type of Cell Therapy
4.3.8. Analysis by Media Compatibility
4.3.9. Analysis by Type of Function
4.3.10. Analysis by Storage Temperature
4.3.11. Analysis by Volume of Media
4.3.12. Analysis by Scale of Operation
4.3.13. Analysis by Application Area
4.3.14. Analysis by Application Area and Geography

4.4. List of Cell Therapy Reagent Providers
4.4.1. Analysis by Year of Establishment
4.4.2. Analysis by Company Size
4.4.3. Analysis by Location of Headquarters
4.4.4. Analysis by Location of Reagent Manufacturing Facilities
4.4.5. Analysis by Certifications / Accreditations Received
4.4.6. Analysis by Type of End-User
4.4.7. Analysis by Type of Cell Therapy
4.4.8. Analysis by Type of Function
4.4.9. Analysis by Storage Temperature
4.4.10. Analysis by Volume of Reagent
4.4.11. Analysis by Scale of Operation
4.4.12. Analysis by Application Area
4.4.13. Analysis by Application Area and Geography

4.5. List of Cell Therapy Extracellular Matrix Providers
4.5.1. Analysis by Year of Establishment
4.5.2. Analysis by Company Size
4.5.3. Analysis by Location of Headquarters
4.5.4. Analysis by Location of Extracellular Matrix Manufacturing Facilities
4.5.5. Analysis by Certifications / Accreditations Received
4.5.6. Analysis by Type of End-User
4.5.7. Analysis by Type of Stem Cell Therapy
4.5.8. Analysis by Type of Function
4.5.9. Analysis by Type of ECM Coating
4.5.10. Analysis by Type of Formulation
4.5.11. Analysis by Shelf Life
4.5.12. Analysis by Storage Temperature
4.5.13. Analysis by Volume of Extracellular Matrix
4.5.14. Analysis by Scale of Operation
4.5.15. Analysis by Application Area
4.5.16. Analysis by Application Area and Geography

5. COMPANY COMPETITIVENESS ANALYSIS
5.1. Chapter Overview
5.2. Key Assumptions and Parameters
5.3. Methodology
5.4. Cell Therapy Consumable Providers: Company Competitiveness Analysis
5.5. Cell Therapy Kits Providers
5.6. Cell Therapy Media Providers
5.6.1. Cell Therapy Media Providers based in North America
5.6.2. Cell Therapy Media Providers based in Europe
5.6.3. Cell Therapy Media Providers based in Asia-Pacific

5.7. Cell Therapy Reagent Providers
5.8. Cell Therapy Extracellular Matrix Providers

6. BRAND POSITIONING OF KEY INDUSTRY PLAYERS
6.1. Chapter Overview
6.2. Scope and Methodology
6.3. Brand Positioning: STEMCELL Technologies
6.4. Brand Positioning: Miltenyi Biotec
6.5. Brand Positioning: Thermo Fisher Scientific
6.6. Brand Positioning: Takara Bio
6.7. Brand Positioning: GeminiBio

7. COMPANY PROFILES
7.1. Chapter Overview
7.2. STEMCELL Technologies
7.2.1. Company Overview
7.2.2. Product Portfolio
7.2.3. Recent Developments and Future Outlook

7.3. Miltenyi Biotec
7.3.1. Company Overview
7.3.2. Product Portfolio
7.3.3. Recent Developments and Future Outlook

7.4. Thermo Fisher Scientific
7.4.1. Company Overview
7.4.2. Product Portfolio
7.4.3. Recent Developments and Future Outlook

7.5. Bio-Techne
7.5.1. Company Overview
7.5.2. Product Portfolio
7.5.3. Recent Developments and Future Outlook

7.6. Irvine Scientific
7.6.1. Company Overview
7.6.2. Product Portfolio
7.6.3. Recent Developments and Future Outlook

7.7. Lonza
7.7.1. Company Overview
7.7.2. Product Portfolio
7.7.3. Recent Developments and Future Outlook

7.8. Sartorius
7.8.1. Company Overview
7.8.2. Product Portfolio
7.8.3. Recent Developments and Future Outlook

7.9. BD Biosciences
7.9.1. Company Overview
7.9.2. Product Portfolio
7.9.3. Recent Developments and Future Outlook

7.10. Corning
7.10.1. Company Overview
7.10.2. Product Portfolio
7.10.3. Recent Developments and Future Outlook

7.11. CellGenix
7.11.1. Company Overview
7.11.2. Product Portfolio
7.11.3. Recent Developments and Future Outlook

8. RECENT DEVELOPMENTS AND INITIATIVES
8.1. Chapter Overview
8.2. Partnership Models

8.3. Cell Therapy Consumables: Partnerships and Collaborations
8.3.1. Analysis by Year of Partnership
8.3.2. Analysis by Type of Partnership
8.3.3. Analysis by Year and Type of Partnership
8.3.4. Analysis by Type of Product
8.3.5. Analysis by Type of Partnership and Type of Product
8.3.6. Analysis by Type of Cell Therapy
8.3.7. Analysis by Type of Product and Type of Cell Therapy
8.3.8. Most Active Players: Analysis by Number of Partnerships
8.3.9. Analysis by Region
8.3.9.1. Intercontinental and Intracontinental Agreements
8.3.9.2. Local and International Agreements

8.4. Cell Therapy Consumables: Mergers and Acquisitions
8.4.1. Cumulative Year-wise Trend of Mergers and Acquisitions
8.4.2. Analysis by Type of Agreement
8.4.3. Analysis by Key Value Drivers
8.4.4. Analysis by Year of Acquisition and Key Value Drivers

8.5. Cell Therapy Consumables: Recent Expansions
8.5.1. Analysis by Year of Expansion
8.5.2. Analysis by Type of Expansion
8.5.3. Analysis by Year and Type of Expansion
8.5.4. Analysis by Type of Product
8.5.5. Analysis by Type of Expansion and Type of Product
8.5.6. Analysis by Area of Expansion
8.5.7. Most Active Players: Analysis by Number of Expansions
8.5.8. Analysis by Region
8.5.8.1. Analysis by Location of Facility (Continent-wise)
8.5.8.2. Analysis by Location of Facility (Country-wise)
8.5.9. Analysis by Type of Expansion and Location of Facility

9. LIKELY PARTNER ANALYSIS FOR CELL THERAPY CONSUMABLE PROVIDERS
9.1. Chapter Overview
9.2. Scoring Criteria and Key Assumptions
9.3. Scope and Methodology
9.4. Key Potential Strategic Partners for Cell Therapy Consumable Providers
9.4.1. Likely Partners for Dendritic Cell Therapy Consumable Providers
9.4.2. Likely Partners for NK Cell Therapy Consumable Providers
9.4.3. Likely Partners for Stem Cell Therapy Consumable Providers
9.4.4. Likely Partners for T-Cell Therapy Consumable Providers

10. ROOTS ANALYSIS PRICING STRATEGY
10.1. Chapter Overview
10.2. Roots Analysis Framework
10.2.1. Theoretical Framework and Price Evaluation Hypothesis for Cell Therapy Media
10.2.1.1. Methodology
10.2.1.2. Results and Interpretation
10.2.1.2.1. Cell Therapy Media Price Evaluation Matrix: Information on Volume of Media
10.2.1.2.2. Cell Therapy Media Price Evaluation Matrix: Information on Media Compatibility
10.2.1.2.3. Cell Therapy Media Price Evaluation Matrix: Information on Type of Product Manufacturing Practices
10.2.1.2.4. Cell Therapy Media Price Evaluation Matrix: Information on Application Area
10.2.1.2.5. Cell Therapy Media Price Evaluation Matrix: Information on Storage Temperature
10.2.1.2.6. Cell Therapy Media Price Evaluation Matrix: Information on Type of Cell Therapy
10.2.1.2.7. Cell Therapy Media Price Evaluation Matrix: Information on Type of Function
10.2.2. Theoretical Framework and Price Evaluation Hypothesis of Cell Therapy Extracellular Matrices
10.2.2.1. Methodology
10.2.2.2. Results and Interpretation
10.2.2.2.1. Cell Therapy Extracellular Matrices Price Evaluation Matrix: Information on Type of ECM Coating
10.2.2.2.2. Cell Therapy Extracellular Matrices Price Evaluation Matrix: Information on Type of Formulation
10.2.2.2.3. Cell Therapy Extracellular Matrices Price Evaluation Matrix: Information on Volume of Extracellular Matrices
10.2.2.2.4. Cell Therapy Extracellular Matrices Price Evaluation Matrix: Information on Storage Temperature
10.2.2.2.5. Cell Therapy Extracellular Matrices Price Evaluation Matrix: Information on Shelf Life
10.2.2.2.6. Cell Therapy Extracellular Matrices Price Evaluation Matrix: Information on Type of Stem Cell Therapy
10.2.2.2.7. Cell Therapy Extracellular Matrices Price Evaluation Matrix: Information on Type of Function

11. DEMAND ANALYSIS
11.1. Chapter Overview
11.2. Scope and Methodology
11.3. Global Demand for Cell Therapy Consumables
11.3.1. Global Demand for Cell Therapy Consumables for Planar Processes
11.3.2. Global Demand for Cell Therapy Consumables for Suspension Processes
11.4. Analysis by Scale of Operation
11.5. Analysis by Geography

12. MARKET FORECAST AND OPPORTUNITY ANALYSIS
12.1. Chapter Overview
12.2. Key Assumptions and Methodology
12.3. Global Cell Therapy Consumables Market, 2023-2035

12.4. Cell Therapy Consumables Market: Analysis by Type of Product
12.4.1. Cell Therapy Consumables Market for Extracellular Matrices, 2023-2035
12.4.2. Cell Therapy Consumables Market for Kits, 2023-2035
12.4.3. Cell Therapy Consumables Market for Media, 2023-2035
12.4.4. Cell Therapy Consumables Market for Reagents, 2023-2035

12.5. Cell Therapy Consumables Market: Analysis by Type of Cell Therapy
12.5.1. Cell Therapy Consumables Market for Dendritic Cell Therapies, 2023-2035
12.5.2. Cell Therapy Consumables Market for NK Cell Therapies, 2023-2035
12.5.3. Cell Therapy Consumables Market for Stem Cell Therapies, 2023-2035
12.5.4. Cell Therapy Consumables Market for T-Cell Therapies, 2023-2035

12.6. Cell Therapy Consumables Market: Analysis by Scale of Operation
12.6.1. Cell Therapy Consumables Market for Clinical Operations, 2023-2035
12.6.2. Cell Therapy Consumables Market for Commercial Operations, 2023-2035

12.7. Cell Therapy Consumables Market: Analysis by Type of End-User
12.7.1. Cell Therapy Consumables Market for Industry Players, 2023-2035
12.7.2. Cell Therapy Consumables Market for Non-Industry Players, 2023-2035

12.8. Cell Therapy Consumables Market: Analysis by Geography
12.8.1. Cell Therapy Consumables Market in North America, 2023-2035
12.8.1.1. Cell Therapy Consumables Market in the US, 2023-2035
12.8.1.2. Cell Therapy Consumables Market in Canada, 2023-2035
12.8.1.3. Cell Therapy Consumables Market in Rest of North America, 2023-2035

12.8.2. Cell Therapy Consumables Market in Europe, 2023-2035
12.8.2.1. Cell Therapy Consumables Market in Spain, 2023-2035
12.8.2.2. Cell Therapy Consumables Market in France, 2023-2035
12.8.2.3. Cell Therapy Consumables Market in Germany, 2023-2035
12.8.2.4. Cell Therapy Consumables Market in Italy, 2023-2035
12.8.2.5. Cell Therapy Consumables Market in the Netherlands, 2023-2035
12.8.2.6. Cell Therapy Consumables Market in the UK, 2023-2035
12.8.2.7. Cell Therapy Consumables Market in Rest of Europe, 2023-2035

12.8.3. Cell Therapy Consumables Market in Asia-Pacific, 2023-2035
12.8.3.1. Cell Therapy Consumables Market in China, 2023-2035
12.8.3.2. Cell Therapy Consumables Market in Korea, 2023-2035
12.8.3.3. Cell Therapy Consumables Market in Rest of Asia-Pacific, 2023-2035

12.8.4. Cell Therapy Consumables Market in Middle East and North Africa, 2023-2035
12.8.5. Cell Therapy Consumables Market in Latin America, 2023-2035

13. UPCOMING TRENDS AND FUTURE GROWTH OPPORTUNITIES
13.1. Chapter Overview
13.2. Emerging Trends Related to Cell Culture Media
13.3. Automation of Cell Therapy Manufacturing Processes
13.4. Single Use Systems and Technologies in Cell Therapy Manufacturing

14. CONCLUDING REMARKS

15. INTERVIEW TRANSCRIPTS
15.1. Chapter Overview
15.2. Akadeum Life Sciences
15.2.1. Interview Transcript: Michael Maloney, Vice President of Business Development - Cell Therapy

15.3. Cellular Engineering Technologies
15.3.1. Interview Transcript: Anant Kamath, Chief Operating Officer

15.4. HiMedia Laboratories
15.4.1. Interview Transcript: Vishal G. Warke, Director R&D, Cell Culture and Immunology and Gauri W. Page, Assistant R&D Manager, Animal Cell Culture

16. APPENDIX I: TABULATED DATA

17. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

Figure 2.1 Executive Summary: Market Landscape
Figure 2.2 Executive Summary: Recent Developments and Initiatives
Figure 2.3 Executive Summary: Demand Analysis
Figure 2.4 Executive Summary: Market Forecast and Opportunity Analysis
Figure 3.1 Types of Cell Therapy Consumables
Figure 4.1 Cell Therapy Consumables: Distribution by Type of Product
Figure 4.2 Cell Therapy Consumable Providers: Distribution by Company Size and Location of Headquarters
Figure 4.3 Cell Therapy Kit Providers: Distribution by Year of Establishment
Figure 4.4 Cell Therapy Kit Providers: Distribution by Company Size
Figure 4.5 Cell Therapy Kit Providers: Distribution by Location of Headquarters
Figure 4.6 Cell Therapy Kit Providers: Distribution by Location of Kit Manufacturing Facilities
Figure 4.7 Cell Therapy Kit Providers: Distribution by Certifications / Accreditations Received
Figure 4.8 Cell Therapy Kit Providers: Distribution by Type of End-User
Figure 4.9 Cell Therapy Kits: Distribution by Type of Cell Therapy
Figure 4.10 Cell Therapy Kits: Distribution by Type of Function
Figure 4.11 Cell Therapy Kits: Distribution by Kit Components
Figure 4.12 Cell Therapy Kits: Distribution by Storage Temperature
Figure 4.13 Cell Therapy Kits: Distribution by Scale of Operation
Figure 4.14 Cell Therapy Kits: Distribution by Application Area
Figure 4.15 Cell Therapy Kit Providers: Distribution by Application Area and Geography
Figure 4.16 Cell Therapy Media Providers: Distribution by Year of Establishment
Figure 4.17 Cell Therapy Media Providers: Distribution by Company Size
Figure 4.18 Cell Therapy Media Providers: Distribution by Location of Headquarters
Figure 4.19 Cell Therapy Media Providers: Distribution by Location of Media ManufacturingFacilities
Figure 4.20 Cell Therapy Media Providers: Distribution by Certifications / Accreditations Received
Figure 4.21 Cell Therapy Media Providers: Distribution by Type of End-User
Figure 4.22 Cell Therapy Media: Distribution by Type of Cell Therapy
Figure 4.23 Cell Therapy Media: Distribution by Media Compatibility
Figure 4.24 Cell Therapy Media: Distribution by Type of Function
Figure 4.25 Cell Therapy Media: Distribution by Storage Temperature
Figure 4.26 Cell Therapy Media: Distribution by Volume of Media
Figure 4.27 Cell Therapy Media: Distribution by Scale of Operation
Figure 4.28 Cell Therapy Media: Distribution by Application Area
Figure 4.29 Cell Therapy Media Providers: Distribution by Application Area and Geography
Figure 4.30 Cell Therapy Reagent Providers: Distribution by Year of Establishment
Figure 4.31 Cell Therapy Reagent Providers: Distribution by Company Size
Figure 4.32 Cell Therapy Reagent Providers: Distribution by Location of Headquarters
Figure 4.33 Cell Therapy Reagent Providers: Distribution by Location of Reagent Manufacturing Facilities
Figure 4.34 Cell Therapy Reagent Providers: Distribution by Certifications / Accreditations Received
Figure 4.35 Cell Therapy Reagent Providers: Distribution by Type of End-User
Figure 4.36 Cell Therapy Reagents: Distribution by Type of Cell Therapy
Figure 4.37 Cell Therapy Reagents: Distribution by Type of Function
Figure 4.38 Cell Therapy Reagents: Distribution by Storage Temperature
Figure 4.39 Cell Therapy Reagents: Distribution by Volume of Reagent
Figure 4.40 Cell Therapy Reagents: Distribution by Scale of Operation
Figure 4.41 Cell Therapy Reagents: Distribution by Application Area
Figure 4.42 Cell Therapy Reagent Providers: Distribution by Application Area and Geography
Figure 4.43 Cell Therapy Extracellular Matrix Providers: Distribution by Year of Establishment
Figure 4.44 Cell Therapy Extracellular Matrix Providers: Distribution by Company Size
Figure 4.45 Cell Therapy Extracellular Matrix Providers: Distribution by Location of Headquarters
Figure 4.46 Cell Therapy Extracellular Matrix Providers: Distribution by Location of Extracellular Matrix Manufacturing Facilities
Figure 4.47 Cell Therapy Extracellular Matrix Providers: Distribution by Certifications / Accreditations Received
Figure 4.48 Cell Therapy Extracellular Matrix Providers: Distribution by Type of End-User
Figure 4.49 Cell Therapy Extracellular Matrices: Distribution by Type of Stem Cell Therapy
Figure 4.50 Cell Therapy Extracellular Matrices: Distribution by Type of Function
Figure 4.51 Cell Therapy Extracellular Matrices: Distribution by Type of ECM Coating
Figure 4.52 Cell Therapy Extracellular Matrices: Distribution by Type of Formulation
Figure 4.53 Cell Therapy Extracellular Matrices: Distribution by Shelf Life
Figure 4.54 Cell Therapy Extracellular Matrices: Distribution by Storage Temperature
Figure 4.55 Cell Therapy Extracellular Matrices: Distribution by Volume of Extracellular Matrix
Figure 4.56 Cell Therapy Extracellular Matrices: Distribution by Scale of Operation
Figure 4.57 Cell Therapy Extracellular Matrices: Distribution by Application Area
Figure 4.58 Cell Therapy Extracellular Matrix Providers: Distribution by Application Area and Geography
Figure 5.1 Company Competitiveness Analysis: Cell Therapy Kit Providers
Figure 5.2 Company Competitiveness Analysis: Cell Therapy Media Providers based in North America
Figure 5.3 Company Competitiveness Analysis: Cell Therapy Media Providers based in Europe
Figure 5.4 Company Competitiveness Analysis: Cell Therapy Media Providers based in Asia-Pacific
Figure 5.5 Company Competitiveness Analysis: Cell Therapy Reagent Providers
Figure 5.6 Company Competitiveness Analysis: Cell Therapy Extracellular Matrix Providers
Figure 6.1 Brand Positioning Matrix: STEMCELL Technologies
Figure 6.2 Brand Positioning Matrix: Miltenyi Biotec
Figure 6.3 Brand Positioning Matrix: Thermo Fisher Scientific
Figure 6.4 Brand Positioning Matrix: Takara Bio
Figure 6.5 Brand Positioning Matrix: GeminiBio
Figure 7.1 STEMCELL Technologies: Product Portfolio
Figure 7.2 Miltenyi Biotec: Product Portfolio
Figure 7.3 Thermo Fisher Scientific: Product Portfolio
Figure 7.4 Bio-Techne: Product Portfolio
Figure 7.5 Irvine Scientific: Product Portfolio
Figure 7.6 Lonza: Product Portfolio
Figure 7.7 Sartorius: Product Portfolio
Figure 7.8 BD Biosciences: Product Portfolio
Figure 7.9 Corning: Product Portfolio
Figure 7.10 CellGenix: Product Portfolio
Figure 8.1 Partnerships and Collaborations: Cumulative Year-wise Trend, 2015-2022
Figure 8.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 8.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Figure 8.4 Partnerships and Collaborations: Distribution by Type of Product
Figure 8.5 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Consumable
Figure 8.6 Partnerships and Collaborations: Distribution by Type of Cell Therapy
Figure 8.7 Partnerships and Collaborations: Distribution by Type of Product and Type of Cell Therapy
Figure 8.8 Most Active Players: Distribution by Number of Partnerships
Figure 8.9 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Figure 8.10 Partnerships and Collaborations: Local and International Agreements
Figure 8.11 Mergers and Acquisitions: Cumulative Year-wise Trend, 2016-2022
Figure 8.12 Mergers and Acquisitions: Distribution by Type of Agreement
Figure 8.13 Mergers and Acquisitions: Distribution by Key Value Drivers
Figure 8.14 Mergers and Acquisitions: Distribution by Year of Acquisition and Key Value Drivers
Figure 8.15 Recent Expansions: Cumulative Year-wise Trend, 2017-2022
Figure 8.16 Recent Expansions: Distribution by Type of Expansion
Figure 8.17 Recent Expansions: Distribution by Year and Type of Expansion
Figure 8.18 Recent Expansions: Distribution by Type of Product
Figure 8.19 Recent Expansions: Distribution by Type of Expansion and Type of Consumable
Figure 8.20 Recent Expansions: Distribution by Area of Expansion (Sq. Ft.)
Figure 8.21 Most Active Players: Distribution by Number of Expansions
Figure 8.22 Recent Expansions: Distribution by Location of Facility (Continent-wise)
Figure 8.23 Recent Expansions: Distribution by Location of Facility (Country-wise)
Figure 8.24 Recent Expansions: Distribution by Type of Expansion and Location of Facility
Figure 10.1 Cell Therapy Media: Roots Analysis Pricing Strategy Matrix
Figure 10.2 Cell Therapy Media: Roots Analysis Pricing Strategy Graphical Interpretation
Figure 10.3 Cell Therapy Extracellular Matrices: Roots Analysis Pricing Strategy Matrix
Figure 10.4 Cell Therapy Extracellular Matrices: Roots Analysis Pricing Strategy Graphical Interpretation
Figure 11.1 Global Demand for Cell Therapy Consumables, 2023-2035 (Thousand Liters)
Figure 11.2 Global Demand for Cell Therapy Consumables for Planar Process, 2023-2035 (Thousand Liters)
Figure 11.3 Global Demand for Cell Therapy Consumables for Suspension Process, 2023-2035 (Thousand Liters)
Figure 11.4 Global Demand for Cell Therapy Consumables for Planar Process, 2023-2035: Distribution by Scale of Operation (Thousand Liters)
Figure 11.5 Global Demand for Cell Therapy Consumables for Suspension Process, 2023-2035: Distribution by Scale of Operation (Thousand Liters)
Figure 11.6 Global Demand for Cell Therapy Consumables: Distribution by Geography, 2023 and 2035
Figure 11.7 Global Demand for Cell Therapy Consumables for Planar Process, 2023-2035: Distribution by Geography (Thousand Liters)
Figure 11.8 Global Demand for Cell Therapy Consumables for Suspension Process, 2023-2035: Distribution by Geography (Thousand Liters)
Figure 12.1 Global Cell Therapy Consumables Market, 2023-2035 (USD Million)
Figure 12.2 Cell Therapy Consumables Market: Distribution by Type of Product, 2023 and 2035
Figure 12.3 Cell Therapy Consumables Market for Extracellular Matrices, 2023-2035 (USD Million)
Figure 12.4 Cell Therapy Consumables Market for Kits, 2023-2035 (USD Million)
Figure 12.5 Cell Therapy Consumables Market for Media, 2023-2035 (USD Million)
Figure 12.6 Cell Therapy Consumables Market for Reagents, 2023-2035 (USD Million)
Figure 12.7 Cell Therapy Consumables Market: Distribution by Type of Cell Therapy, 2023, 2028 and 2035
Figure 12.8 Cell Therapy Consumables Market for Dendritic Cell Therapies, 2023-2035 (USD Million)
Figure 12.9 Cell Therapy Consumables Market for NK Cell Therapies, 2023-2035 (USD Million)
Figure 12.10 Cell Therapy Consumables Market for Stem Cell Therapies, 2023-2035 (USD Million)
Figure 12.11 Cell Therapy Consumables Market for T-Cell Therapies, 2023-2035 (USD Million)
Figure 12.12 Cell Therapy Consumables Market: Distribution by Scale of Operation, 2023 and 2035
Figure 12.13 Cell Therapy Consumables Market for Clinical Operations, 2023-2035 (USD Million)
Figure 12.14 Cell Therapy Consumables Market for Commercial Operations, 2023-2035 (USD Million)
Figure 12.15 Cell Therapy Consumables Market: Distribution by Type of End-User, 2023 and 2035
Figure 12.16 Cell Therapy Consumables Market for Industry Players, 2023-2035 (USD Million)
Figure 12.17 Cell Therapy Consumables Market for Non-Industry Players, 2023-2035 (USD Million)
Figure 12.18 Cell Therapy Consumables Market: Distribution by Geography, 2023 and 2035
Figure 12.19 Cell Therapy Consumables Market in North America, 2023-2035 (USD Million)
Figure 12.20 Cell Therapy Consumables Market in the US, 2023-2035 (USD Million)
Figure 12.21 Cell Therapy Consumables Market in Canada, 2023-2035 (USD Million)
Figure 12.22 Cell Therapy Consumables Market in Rest of North America, 2023-2035 (USD Million)
Figure 12.23 Cell Therapy Consumables Market in Europe, 2023-2035 (USD Million)
Figure 12.24 Cell Therapy Consumables Market in Spain, 2023-2035 (USD Million)
Figure 12.25 Cell Therapy Consumables Market in France, 2023-2035 (USD Million)
Figure 12.26 Cell Therapy Consumables Market in Germany, 2023-2035 (USD Million)
Figure 12.27 Cell Therapy Consumables Market in Italy, 2023-2035 (USD Million)
Figure 12.28 Cell Therapy Consumables Market in the Netherlands, 2023-2035 (USD Million)
Figure 12.29 Cell Therapy Consumables Market in the UK, 2023-2035 (USD Million)
Figure 12.30 Cell Therapy Consumables Market in Rest of Europe, 2023-2035 (USD Million)
Figure 12.31 Cell Therapy Consumables Market in Asia-Pacific, 2023-2035 (USD Million)
Figure 12.32 Cell Therapy Consumables Market in China, 2023-2035 (USD Million)
Figure 12.33 Cell Therapy Consumables Market in Korea, 2023-2035 (USD Million)
Figure 12.34 Cell Therapy Consumables Market in Rest of Asia-Pacific, 2023-2035 (USD Million)
Figure 12.35 Cell Therapy Consumables Market in Middle East and North Africa, 2023-2035 (USD Million)
Figure 12.36 Cell Therapy Consumables Market in Latin America, 2023-2035 (USD Million)
Figure 14.1 Concluding Remarks: Overall Market Landscape
Figure 14.2 Concluding Remarks: Recent Developments
Figure 14.3 Concluding Remarks: Demand Analysis
Figure 14.4 Concluding Remarks: Market Forecast and Opportunity Analysis
Figure 14.5 Concluding Remarks: Market Forecast and Opportunity Analysis

List Of Tables

Table 3.1 Cell Therapies: Applications
Table 3.2 Differences between Cell Therapies and Other Biopharmaceuticals
Table 3.3 Key Cell Therapy Manufacturing Steps
Table 3.4 Types of Media Used in Cell Therapy Manufacturing
Table 4.1 List of Cell Therapy Kit Providers
Table 4.2 Cell Therapy Kits: Information on Type of Cell Therapy and Type of Function
Table 4.3 Cell Therapy Kits: Information on Kit Components and Storage Temperature
Table 4.4 Cell Therapy Kits: Information on Scale of Operation and Application Area
Table 4.5 List of Cell Therapy Media Providers
Table 4.6 Cell Therapy Media: Information on Type of Cell Therapy, Media Compatibility and Type of Function
Table 4.7 Cell Therapy Media: Information on Storage Temperature and Volume of Media
Table 4.8 Cell Therapy Media: Information on Scale of Operation and Application Area
Table 4.9 List of Cell Therapy Reagent Providers
Table 4.10 Cell Therapy Reagents: Information on Type of Cell Therapy and Type of Function
Table 4.11 Cell Therapy Reagents: Information on Storage Temperature and Volume of Reagent
Table 4.12 Cell Therapy Reagents: Information on Scale of Operation and Application Area
Table 4.13 List of Cell Therapy Extracellular Matrix Providers
Table 4.14 Cell Therapy Extracellular Matrices: Information on Type of Stem Cell Therapy and Type of Function
Table 4.15 Cell Therapy Extracellular Matrices: Information on Type of ECM Coating and Type of Formulation
Table 4.16 Cell Therapy Extracellular Matrices: Information on Shelf Life, Storage Temperature and Volume of Extracellular Matrix
Table 4.17 Cell Therapy Extracellular Matrices: Information on Scale of Operation and Application Area
Table 7.1 STEMCELL Technologies: Company Overview
Table 7.2 STEMCELL Technologies: Recent Developments and Future Outlook
Table 7.3 Miltenyi Biotec: Company Overview
Table 7.4 Miltenyi Biotec: Recent Developments and Future Outlook
Table 7.5 Thermo Fisher Scientific: Company Overview
Table 7.6 Thermo Fisher Scientific: Recent Developments and Future Outlook
Table 7.7 Bio-Techne: Company Overview
Table 7.8 Bio-Techne: Recent Developments and Future Outlook
Table 7.9 Irvine Scientific: Company Overview
Table 7.10 Irvine Scientific: Recent Developments and Future Outlook
Table 7.11 Lonza: Company Overview
Table 7.12 Sartorius: Company Overview
Table 7.13 Sartorius: Recent Developments and Future Outlook
Table 7.14 BD Biosciences: Company Overview
Table 7.15 BD Biosciences: Recent Developments and Future Outlook
Table 7.16 Corning: Company Overview
Table 7.17 CellGenix: Company Overview
Table 7.18 CellGenix: Recent Developments and Future Outlook
Table 8.1 Cell Therapy Consumables: List of Partnerships and Collaborations, 2015-2022
Table 8.2 Cell Therapy Consumables: Information on Location of Headquarters, 2015-2022
Table 8.3 Mergers and Acquisitions: List of Mergers and Acquisitions, 2016-2022
Table 8.4 Mergers and Acquisitions: Information on Key Value Drivers, 2016-2022
Table 8.5 Cell Therapy Consumables: List of Recent Expansions, 2017-2022
Table 9.1 Key Potential Strategic Partners for Cell Therapy Consumable Providers
Table 9.2 Likely Partners for Dendritic Cell Therapy Consumable Providers
Table 9.3 Likely Partners for NK Cell Therapy Consumable Providers
Table 9.4 Likely Partners for Stem Cell Therapy Consumable Providers
Table 9.5 Likely Partners for T-Cell Therapy Consumable Providers
Table 10.1 Media Price Evaluation Matrix: Based on Volume of Media
Table 10.2 Media Price Evaluation Matrix: Based on Media Compatibility
Table 10.3 Media Price Evaluation Matrix: Based on Type of Product Manufacturing Practices
Table 10.4 Media Price Evaluation Matrix: Based on Application Area
Table 10.5 Media Price Evaluation Matrix: Based on Storage Temperature
Table 10.6 Media Price Evaluation Matrix: Based on Type of Cell Therapy
Table 10.7 Media Price Evaluation Matrix: Based on Type of Function
Table 10.8 ECM Price Evaluation Matrix: Based on Type of ECM Coating
Table 10.9 ECM Price Evaluation Matrix: Based on Type of Formulation
Table 10.10 ECM Price Evaluation Matrix: Based on Volume of Extracellular Matrix
Table 10.11 ECM Price Evaluation Matrix: Based on Storage Temperature
Table 10.12 ECM Price Evaluation Matrix: Based on Shelf Life
Table 10.13 ECM Price Evaluation Matrix: Based on Type of Stem Cell Therapy
Table 10.14 ECM Price Evaluation Matrix: Based on Type of Function
Table 15.1 Akadeum Life Sciences: Key Highlights
Table 15.2 Cellular Engineering Technologies: Key Highlights
Table 15.3 HiMedia Laboratories: Key Highlights
Table 16.1 Cell Therapy Consumables: Distribution by Type of Product
Table 16.2 Cell Therapy Consumable Providers: Distribution by Company Size and Location of Headquarters
Table 16.3 Cell Therapy Kit Providers: Distribution by Year of Establishment
Table 16.4 Cell Therapy Kit Providers: Distribution by Company Size
Table 16.5 Cell Therapy Kit Providers: Distribution by Location of Headquarters
Table 16.6 Cell Therapy Kit Providers: Distribution by Location of Kit Manufacturing Facilities
Table 16.7 Cell Therapy Kit Providers: Distribution by Certifications / Accreditations Received
Table 16.8 Cell Therapy Kit Providers: Distribution by Type of End-User
Table 16.9 Cell Therapy Kits: Distribution by Type of Cell Therapy
Table 16.10 Cell Therapy Kits: Distribution by Type of Function
Table 16.11 Cell Therapy Kits: Distribution by Kit Components
Table 16.12 Cell Therapy Kits: Distribution by Storage Temperature
Table 16.13 Cell Therapy Kits: Distribution by Scale of Operation
Table 16.14 Cell Therapy Kits: Distribution by Application Area
Table 16.15 Cell Therapy Media Providers: Distribution by Year of Establishment
Table 16.16 Cell Therapy Media Providers: Distribution by Company Size
Table 16.17 Cell Therapy Media Providers: Distribution by Location of Headquarters
Table 16.18 Cell Therapy Media Providers: Distribution by Location of Media Manufacturing Facilities
Table 16.19 Cell Therapy Media Providers: Distribution by Certifications / Accreditations Received
Table 16.20 Cell Therapy Media Providers: Distribution by Type of End-User
Table 16.21 Cell Therapy Media: Distribution by Type of Cell Therapy
Table 16.22 Cell Therapy Media: Distribution by Media Compatibility
Table 16.23 Cell Therapy Media: Distribution by Type of Function
Table 16.24 Cell Therapy Media: Distribution by Storage Temperature
Table 16.25 Cell Therapy Media: Distribution by Volume of Media
Table 16.26 Cell Therapy Media: Distribution by Scale of Operation
Table 16.27 Cell Therapy Media: Distribution by Application Area
Table 16.28 Cell Therapy Reagent Providers: Distribution by Year of Establishment
Table 16.29 Cell Therapy Reagent Providers: Distribution by Company Size
Table 16.30 Cell Therapy Reagent Providers: Distribution by Location of Headquarters
Table 16.31 Cell Therapy Reagent Providers: Distribution by Location of Reagent Manufacturing Facilities
Table 16.32 Cell Therapy Reagent Providers: Distribution by Certifications / Accreditations Received
Table 16.33 Cell Therapy Reagent Providers: Distribution by Type of End-User
Table 16.34 Cell Therapy Reagents: Distribution by Type of Cell Therapy
Table 16.35 Cell Therapy Reagents: Distribution by Type of Function
Table 16.36 Cell Therapy Reagents: Distribution by Storage Temperature
Table 16.37 Cell Therapy Reagents: Distribution by Volume of Reagent
Table 16.38 Cell Therapy Reagents: Distribution by Scale of Operation
Table 16.39 Cell Therapy Reagents: Distribution by Application Area
Table 16.40 Cell Therapy Extracellular Matrix Providers: Distribution by Year of Establishment
Table 16.41 Cell Therapy Extracellular Matrix Providers: Distribution by Company Size
Table 16.42 Cell Therapy Extracellular Matrix Providers: Distribution by Location of Headquarters
Table 16.43 Cell Therapy Extracellular Matrix Providers: Distribution by Location of Extracellular Matrix Manufacturing Facilities
Table 16.44 Cell Therapy Extracellular Matrix Providers: Distribution by Certifications / Accreditations Received
Table 16.45 Cell Therapy Extracellular Matrix Providers: Distribution by Type of End-User
Table 16.46 Cell Therapy Extracellular Matrices: Distribution by Type of Stem Cell Therapy
Table 16.47 Cell Therapy Extracellular Matrices: Distribution by Type of Function
Table 16.48 Cell Therapy Extracellular Matrices: Distribution by Type of ECM Coating
Table 16.49 Cell Therapy Extracellular Matrices: Distribution by Type of Formulation
Table 16.50 Cell Therapy Extracellular Matrices: Distribution by Shelf Life
Table 16.51 Cell Therapy Extracellular Matrices: Distribution by Storage Temperature
Table 16.52 Cell Therapy Extracellular Matrices: Distribution by Volume of Extracellular Matrix
Table 16.53 Cell Therapy Extracellular Matrices: Distribution by Scale of Operation
Table 16.54 Cell Therapy Extracellular Matrices: Distribution by Application Area
Table 16.55 Partnerships and Collaborations: Cumulative Year-wise Trend, 2015-2022
Table 16.56 Partnerships and Collaborations: Distribution by Type of Partnership
Table 16.57 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partnership, 2015-2022
Table 16.58 Partnerships and Collaborations: Distribution by Type of Product
Table 16.59 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Consumable
Table 16.60 Partnerships and Collaborations: Distribution by Type of Cell Therapy
Table 16.61 Partnerships and Collaborations: Distribution by Type of Product and Type of Cell Therapy
Table 16.62 Most Active Players: Distribution by Number of Partnerships
Table 16.63 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Table 16.64 Partnerships and Collaborations: Local and International Agreements
Table 16.65 Mergers and Acquisitions: Cumulative Year-wise Trend, 2016-2022
Table 16.66 Mergers and Acquisitions: Distribution by Type of Agreement
Table 16.67 Mergers and Acquisitions: Distribution by Key Value Drivers
Table 16.68 Mergers and Acquisitions: Distribution by Year of Acquisition and Key Value Drivers, 2016-2022
Table 16.69 Recent Expansions: Cumulative Year-wise Trend, 2017-2022
Table 16.70 Recent Expansions: Distribution by Type of Expansion
Table 16.71 Recent Expansions: Distribution by Year and Type of Expansion, 2017-2022
Table 16.72 Recent Expansions: Distribution by Type of Product
Table 16.73 Recent Expansions: Distribution by Type of Expansion and Type of Product
Table 16.74 Recent Expansions: Distribution by Area of Expansion
Table 16.75 Most Active Players: Distribution by Number of Expansions
Table 16.76 Recent Expansions: Distribution by Location of Facility (Continent-wise)
Table 16.77 Recent Expansions: Distribution by Location of Facility (Country-wise)
Table 16.78 Recent Expansions: Distribution by Type of Expansion and Location of Facility
Table 16.79 Global Demand for Cell Therapy Consumables, 2023-2035 (Thousand Liters)
Table 16.80 Global Demand for Cell Therapy Consumables for Planar Process, 2023-2035 (Thousand Liters)
Table 16.81 Global Demand for Cell Therapy Consumables for Suspension Process, 2023-2035 (Thousand Liters)
Table 16.82 Global Demand for Cell Therapy Consumables for Planar Process, 2023-2035: Distribution by Scale of Operation (Thousand Liters)
Table 16.83 Global Demand for Cell Therapy Consumables for Suspension Process, 2023-2035: Distribution by Scale of Operation (Thousand Liters)
Table 16.84 Global Demand for Cell Therapy Consumables: Distribution by Geography, 2023 and 2035
Table 16.85 Global Demand for Cell Therapy Consumables for Planar Process, 2023-2035: Distribution by Geography (Thousand Liters)
Table 16.86 Global Demand for Cell Therapy Consumables for Suspension Process, 2023-2035: Distribution by Geography (Thousand Liters)
Table 16.87 Global Cell Therapy Consumables Market, 2023-2035 (USD Million)
Table 16.88 Cell Therapy Consumables Market: Distribution by Type of Product, 2023 and 2035
Table 16.89 Cell Therapy Consumables Market for Extracellular Matrices, 2023-2035 (USD Million)
Table 16.90 Cell Therapy Consumables Market for Kits, 2023-2035 (USD Million)
Table 16.91 Cell Therapy Consumables Market for Media, 2023-2035 (USD Million)
Table 16.92 Cell Therapy Consumables Market for Reagents, 2023-2035 (USD Million)
Table 16.93 Cell Therapy Consumables Market: Distribution by Type of Cell Therapy, 2023, 2028 and 2035
Table 16.94 Cell Therapy Consumables Market for Dendritic Cell Therapies, 2023-2035 (USD Million)
Table 16.95 Cell Therapy Consumables Market for NK Cell Therapies, 2023-2035 (USD Million)
Table 16.96 Cell Therapy Consumables Market for Stem Cell Therapies, 2023-2035 (USD Million)
Table 16.97 Cell Therapy Consumables Market for T-Cell Therapies, 2023-2035 (USD Million)
Table 16.98 Cell Therapy Consumables Market: Distribution by Scale of Operation, 2023 and 2035
Table 16.99 Cell Therapy Consumables Market for Clinical Operations, 2023-2035 (USD Million)
Table 16.100 Cell Therapy Consumables Market for Commercial Operations, 2023-2035 (USD Million)
Table 16.101 Cell Therapy Consumables Market: Distribution by Type of End-User, 2023 and 2035
Table 16.102 Cell Therapy Consumables Market for Industry Players, 2023-2035 (USD Million)
Table 16.103 Cell Therapy Consumables Market for Non-Industry Players, 2023-2035 (USD Million)
Table 16.104 Cell Therapy Consumables Market: Distribution by Geography, 2023 and 2035
Table 16.105 Cell Therapy Consumables Market in North America, 2023-2035 (USD Million)
Table 16.106 Cell Therapy Consumables Market in the US, 2023-2035 (USD Million)
Table 16.107 Cell Therapy Consumables Market in Canada, 2023-2035 (USD Million)
Table 16.108 Cell Therapy Consumables Market in Rest of North America, 2023-2035 (USD Million)
Table 16.109 Cell Therapy Consumables Market in Europe, 2023-2035 (USD Million)
Table 16.110 Cell Therapy Consumables Market in Spain, 2023-2035 (USD Million)
Table 16.111 Cell Therapy Consumables Market in France, 2023-2035 (USD Million)
Table 16.112 Cell Therapy Consumables Market in Germany, 2023-2035 (USD Million)
Table 16.113 Cell Therapy Consumables Market in Italy, 2023-2035 (USD Million)
Table 16.114 Cell Therapy Consumables Market in the Netherlands, 2023-2035 (USD Million)
Table 16.115 Cell Therapy Consumables Market in the UK, 2023-2035 (USD Million)
Table 16.116 Cell Therapy Consumables Market in Rest of Europe, 2023-2035 (USD Million)
Table 16.117 Cell Therapy Consumables Market in Asia-Pacific, 2023-2035 (USD Million)
Table 16.118 Cell Therapy Consumables Market in China, 2023-2035 (USD Million)
Table 16.119 Cell Therapy Consumables Market in Korea, 2023-2035 (USD Million)
Table 16.120 Cell Therapy Consumables Market in Rest of Asia-Pacific, 2023-2035 (USD Million)
Table 16.121 Cell Therapy Consumables Market in Middle East and North Africa, 2023-2035 (USD Million)
Table 16.122 Cell Therapy Consumables Market in Latin America, 2023-2035 (USD Million)

List Of Companies

The following companies and organizations have been mentioned in the report:

  1. Accellta
  2. Acer Therapeutics
  3. ACROBiosystems
  4. Activartis Biotech
  5. AddLife
  6. Adicet Bio
  7. Aduro Biotech
  8. Advanced BioMatrix (Acquired by BICO)
  9. Advent Bioservices
  10. AGC Biologics
  11. AgenTus Therapeutics
  12. Agilent Technologies
  13. Ajinomoto
  14. Akadeum Life Sciences
  15. Akron Biotech
  16. Allele Biotechnology and Pharmaceuticals
  17. Allife Medical Science and Technology
  18. Allogene Therapeutics
  19. Altor BioScience
  20. American CryoStem
  21. Amphera
  22. AMSBIO
  23. ANI Pharmaceuticals
  24. apceth Biopharma
  25. Applied Biological Materials
  26. Applied Cells
  27. Arbele
  28. Arcline Investment Management
  29. Argos Therapeutics
  30. Aspire Health Science
  31. Asterias Biotherapeutics
  32. ATCC
  33. Athersys
  34. Atlantis Bioscience
  35. Atreca
  36. Aurora Biopharma
  37. Austrianova
  38. Autolus
  39. Avantor
  40. AVAX Technologies
  41. Axion BioSystems
  42. Axol Bioscience
  43. Basic Pharma
  44. BD Biosciences
  45. Beijing Biohealthcare Biotechnology
  46. Beijing Doing Biomedical
  47. Beijing Immunochina Medical Science & Technology
  48. Beijing Sanwater Biological Technology
  49. Beijing Tricision Biotherapeutics 
  50. Bellicum Pharmaceuticals
  51. Bio Elpida
  52. BioAtla
  53. BioCardia
  54. BioCare
  55. BioCentriq
  56. Bio-Connect
  57. BioInno Bioscience
  58. Bioinova
  59. Biological Industries
  60. BioRestorative Therapies
  61. Bio-Techne 
  62. Biowest
  63. Bone Therapeutics
  64. BrainStorm Cell Therapeutics
  65. Brigham and Women’s Hospital
  66. C3i (Center of Excellence for Cellular Therapy)
  67. Caladrius Biosciences
  68. Capricor Therapeutics
  69. Captain T Cell
  70. Captivate Bio
  71. CardioCell
  72. Carina Biotech
  73. CARsgen Therapeutics
  74. CAR-T (Shanghai) Biotechnology
  75. Cartherics
  76. Celixir
  77. Cell and Gene Therapy Catapult
  78. Cell Applications
  79. Cell Biologics
  80. Cell Biotech
  81. Cell Culture Technologies
  82. Cell Systems
  83. Cell Therapies
  84. Cell-Easy
  85. Cellectis
  86. CellGenix
  87. Cellin Technologies
  88. Cellmed
  89. CellMP (A subsidiary of Emmecell)
  90. CELLnTEC Advanced Cell Systems
  91. CellPraxis
  92. CellProtect Nordic Pharmaceuticals
  93. CellProthera
  94. Cells for Cells 
  95. Cells Online
  96. CellSystems
  97. Cellular Biomedicine Group
  98. Cellular Engineering Technologies
  99. Cellular Therapeutics
  100. Celprogen
  101. Celularity
  102. Celyad
  103. Censo Biotechnologies
  104. CHA Biolab
  105. Chengdu MedGenCell
  106. CiMaas
  107. Cincinnati Children’s Hospital Medical Center
  108. Clean Cells
  109. CO.DON
  110. Cogent Biosciences
  111. Cognate BioServices
  112. CoImmune
  113. CollPlant
  114. Cook MyoSite
  115. Corestem
  116. Corning
  117. Creative Bioarray
  118. Creative Biolabs
  119. CRISPR Therapeutics
  120. Cyagen
  121. Cytiva
  122. Cytopeutics
  123. CytoSen Therapeutics (Acquired by Kiadis Pharma)
  124. Cytovac
  125. CyTuVax 
  126. DanDrit Biotech
  127. DCPrime
  128. Delta-Vir
  129. denovoMATRIX
  130. DiscGenics
  131. ElevateBio
  132. Endocyte
  133. Eureka Therapeutics
  134. Eutilex
  135. EXUMA Biotech
  136. Fate Therapeutics
  137. Fibrocell Technologies
  138. Five Prime Therapeutics
  139. Formula Pharmaceuticals
  140. Fortress Biotech
  141. Froceth
  142. FroggaBio
  143. FUJIFILM Cellular Dynamics
  144. FUJIFILM Wako Pure Chemicals
  145. Gadeta
  146. Gamida Cell
  147. GE Healthcare
  148. GeminiBio
  149. GenCure
  150. GenCure (A subsidiary of BioBridge Global)
  151. GenIbet Biopharmaceuticals
  152. GigaGen 
  153. Global Cell Med
  154. Glycostem Therapeutics
  155. Gradalis
  156. GRI Bio
  157. Guangzhou Trinomab Biotech
  158. Heat Biologics
  159. Hebei Senlang Biotechnology
  160. Hemostemix
  161. HengRui YuanZheng Bio-Technology
  162. HiMedia Laboratories
  163. Histocell
  164. Histogenics
  165. Hitachi Chemical
  166. Holostem Terapie Avanzate
  167. Hunan Zhaotai Yongren Biotech
  168. IBA Lifesciences
  169. iCarTAB BioMed
  170. iCell Gene Therapeutics
  171. Immatics
  172. Immune Therapeutics
  173. Immunicum
  174. ImmunoCellular Therapeutics
  175. Immunovative Therapies 
  176. Immutep
  177. IncoCell Tianjin (A subsidiary of Boyalife)
  178. Incysus
  179. Innoprot
  180. Innovative Cellular Therapeutics
  181. inRegen
  182. International Stem Cell Corporation
  183. InVitria
  184. Iovance Biotherapeutics
  185. Irvine Scientific (Acquired by FUJIFILM)
  186. ISTO Technologies
  187. Ivy Life Sciences
  188. iXCells Biotechnologies
  189. Japan Tissue Engineering
  190. JSR 
  191. JW Biotechnology
  192. JW CreaGene
  193. Kadimastem
  194. Kangstem Biotech
  195. Kiadis Pharma
  196. Kiromic
  197. Kuur Therapeutics
  198. LAgen Laboratories
  199. Laurus Labs
  200. Laurus Bio
  201. Leucid Bio
  202. Life Technologies
  203. Lifecells
  204. Lifeline Cell Technology
  205. Lineage Cell Therapeutics
  206. Lion TCR
  207. Living Pharma
  208. Longeveron
  209. Lonza
  210. Lumos Pharma
  211. Lyell Immunopharma
  212. Lykan Bioscience
  213. Marino Biotechnology
  214. Matrixome
  215. MaxCyte
  216. MBL Beijing Biotech
  217. Medeor Therapeutics
  218. MEDianus Pharma
  219. Medigene
  220. MEDINET
  221. MedVax Technologies
  222. Mesoblast
  223. Metrion Biosciences
  224. Miltenyi Biotech
  225. Minerva Biotechnologies
  226. Minovia Therapeutics
  227. MolecuVax
  228. Moraga Biotechnology
  229. MultiClonal Therapeutics
  230. Multimmune
  231. Multus Biotechnology
  232. Mustang Bio 
  233. Nanjing KAEDI Biotechnology
  234. NantKwest
  235. NeuCyte
  236. Neuralstem
  237. Neuromics
  238. Nikon CeLL innovation
  239. Nkarta
  240. Nohla Therapeutics
  241. Noile-Immune Biotech
  242. Northern Therapeutics
  243. Northwest Biotherapeutics
  244. Novadip Biosciences
  245. NovaRx (Acquired by Viropro)
  246. Novex Innovations
  247. Nucleus Biologics
  248. Nuo Therapeutics
  249. Octapharma
  250. OiDE BetaRevive
  251. Ology Bioservices
  252. Omni Lifesciences
  253. Oncobiomed
  254. Opexa Therapeutics
  255. Orchard Therapeutics
  256. OrganaBio
  257. Ori Biotech
  258. Pall Corporation
  259. PAN-Biotech
  260. PBS Biotech
  261. PDC*line Pharma
  262. PELOBiotech
  263. PeproTech
  264. PersonGen BioTherapeutics
  265. PharmaBio
  266. Pharmicell
  267. PhoenixSongs Biologicals
  268. Pinze Lifetechnology
  269. Pique Therapeutics
  270. Pluristem Therapeutics
  271. Plus Therapeutics
  272. Poseida Therapeutics
  273. Precision BioSciences
  274. Preferred Cell Systems™
  275. Pregene ShenZhen Biotechnology
  276. Primorigen Biosciences (Acquired by Nucleus Biologics)
  277. ProMab Biotechnologies
  278. Promethera Biosciences
  279. PromoCell
  280. Propagenix
  281. Provia Laboratories
  282. R&D Systems
  283. ReachBio Research Labs
  284. Regeneris Medical
  285. Regeneus
  286. ReNeuron
  287. REPROCELL
  288. Rexgenero
  289. RHEACELL
  290. Riyadh Pharma
  291. ROKIT Healthcare
  292. RoosterBio
  293. Roslin Cell Therapies
  294. Rousselot Biomedical
  295. Rubius Therapeutics
  296. S.Biomedics
  297. Sangamo Therapeutics
  298. Sanvitra
  299. Saronic Biotechnology
  300. Sartorius
  301. Sartorius Korea Biotech (A subsidiary of Sartorius)
  302. Sartorius Stedim Biotech
  303. ScienCell Research Laboratories
  304. Scinogy
  305. Sclnow Biotechnology
  306. SCM Lifescience
  307. Sentien Biotechnologies
  308. Shanghai Bioray Laboratory
  309. Shanghai Houchao Biotechnology
  310. Shanghai iCELL Biotechnology
  311. Shanghai Longyao Biotechnology
  312. Shanghai Unicar-Therapy Bio-medicine Technology
  313. Shenzhen BinDeBio
  314. Shenzhen Hornetcorn Biotechnology
  315. Sigma-Aldrich
  316. Sinobioway Cell Therapy
  317. SMT Bio
  318. Sorrento Therapeutics
  319. SQZ Biotechnologies
  320. Stem Cell Arabia
  321. STEMCELL Technologies
  322. StemImmune
  323. Stemmatters 
  324. Super-T Cell Cancer Company
  325. Surface Oncology
  326. Tactiva Therapeutics
  327. Taiwan Bio Therapeutics
  328. Takara Bio
  329. TapImmune 
  330. Targazyme
  331. TC BioPharm
  332. TCR2 Therapeutics
  333. Tella
  334. Tessa Therapeutics
  335. The Discovery Labs Center for Breakthrough Medicines
  336. Thermo Fisher Scientific
  337. ThermoGenesis
  338. Tianhe Stem Cell Biotechnologies
  339. Tianjin Ever Union Biotechnology 
  340. TiGenix
  341. TILT Biotherapeutics
  342. Tmunity Therapeutics
  343. TNK Therapeutics
  344. TotipotentRX
  345. TRACT Therapeutics
  346. TransCure BioServices
  347. TransGen Biotech
  348. TreeFrog Therapeutics
  349. TRINOVA BIOCHEM
  350. Triumvira Immunologics
  351. TVAX Biomedical
  352. U.S. Stem Cell
  353. United States Biological
  354. Universal Cells
  355. Vaccinogen
  356. Vericel
  357. VetStem Biopharma
  358. Vinasets
  359. ViroMed
  360. Viscofan BioEngineering
  361. Vitro Biopharma
  362. Vivo Bio Tech
  363. Waisman Biomanufacturing
  364. West Biotherapy
  365. WiCell
  366. Wissenschaftlicher Service Pharma (WiSP)
  367. Worchester Polytechnic Institute
  368. Wuhan Sian Medical Technology
  369. Xcell Therapeutics
  370. Xcelthera
  371. XEME Biopharma
  372. ZellBio
  373. Zelluna Immunotherapy
  374. Ziopharm Oncology

Source 1: https://www.thermofisher.com/blog/behindthebench/raw-material-considerations-cell-therapy/
Source 2: https://www.cellandgene.com/doc/cell-gene-therapies-investment-outlook-in-beyond-0001

PRICING DETAILS

USD 4,799

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license grants the right of use of the purchased report by a department / team of individuals (up to 12) in a particular organization. The license does not limit the use to a particular site / office location. The report may be accessed on the computer read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com